Thus, we considered that an agonist that could simultaneously activate PPAR α and γ (Fig. 1) might provide an alternative strategy for the treatment of insulin resistance and dyslipidemia without undesirable side effect. This evidence concerns the gene PPARA and metabolic syndrome.